Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | S100A10 |
| Gene Name: | S100A10 |
| Protein Full Name: | Protein S100-A10 |
| Alias: | Annexin II ligand calpactin I light polypeptide; ANX2L; ANX2LG; CAL1L; Calgizzarin; CLp11; P11; S100 calcium binding protein A10; S100 calcium-binding protein A10; S10AA |
| Mass (Da): | 11203 |
| Number AA: | 97 |
| UniProt ID: | P60903 |
| Locus ID: | 6281 |
| COSMIC ID: | S100A10 |
| Gene location on chromosome: | 1q21.3 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.08 |
| Normal role description: | S100A10 is a calcium binding-like protein, but does not actually bind calcium due to amino acid replacements in its calcium-binding loops that lock the protein in a permanently active state. Because S100A10 induces the dimerization of ANXA2/p36, it may function as a regulator of protein phosphorylation in that the ANXA2 monomer is the preferred target (in vitro) of tyrosine-specific kinase. It may also function in exo- and endocytosis, and in the regulation of plasminogen/ plasmin activity. It has been found to be up-regulated in a number of cancers, but no mutations that cause congenital anomalies have been found. |